Furthermore, a recent study by Datta et al. showed that WRN inhibitor can potentiate the cytotoxicity of olaparib in BRCA2-mutated ovarian cancer cells that otherwise normally exhibit de novo or acquired PARPi resistance [95]. The gene discussed is BRCA2; the disease is ovarian cancer.